Last reviewed · How we verify
Levothyroxine Tablet
Levothyroxine is a synthetic thyroid hormone that replaces or supplements endogenous thyroid hormone to restore normal metabolic function.
Levothyroxine is a synthetic thyroid hormone that replaces or supplements endogenous thyroid hormone to restore normal metabolic function. Used for Hypothyroidism, Thyroid cancer suppression therapy, Myxedema coma.
At a glance
| Generic name | Levothyroxine Tablet |
|---|---|
| Also known as | Tirosint |
| Sponsor | University of California, Los Angeles |
| Drug class | Thyroid hormone replacement |
| Target | Thyroid hormone receptor (TR-alpha and TR-beta) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology |
| Phase | FDA-approved |
Mechanism of action
Levothyroxine (T4) is converted peripherally to the active form triiodothyronine (T3), which binds to thyroid hormone receptors in target tissues to regulate metabolism, growth, and development. It is used to treat hypothyroidism by restoring circulating thyroid hormone levels to normal physiological ranges, thereby normalizing metabolic rate and alleviating symptoms of thyroid hormone deficiency.
Approved indications
- Hypothyroidism
- Thyroid cancer suppression therapy
- Myxedema coma
Common side effects
- Tachycardia
- Tremor
- Anxiety
- Insomnia
- Heat intolerance
- Palpitations
Key clinical trials
- T4/T3 Therapy in Hypothyroidism (PHASE2)
- Thyroid Hormone for Treatment of Nonalcoholic Steatohepatitis in Veterans (PHASE2)
- Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy
- COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer (PHASE2)
- Sunitinib or Cediranib for Alveolar Soft Part Sarcoma (PHASE2)
- Levothyroxine as Adjuvant to a Hypocaloric Diet for the Treatment of Obesity. (PHASE3)
- A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants (PHASE2, PHASE3)
- Use of Tirosint®-SOL or Tablet Formulations of Levothyroxine in Pediatric Patients With Congenital Hypothyroidism (CH) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levothyroxine Tablet CI brief — competitive landscape report
- Levothyroxine Tablet updates RSS · CI watch RSS
- University of California, Los Angeles portfolio CI